USANA Health Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a USNA research report →
Range $35 – $35
Price Chart
About the company
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer.
- CEO
- Kevin G. Guest
- IPO
- 1994
- Employees
- 1,570
- HQ
- Salt Lake City, UT, US
Get TickerSpark's AI analysis on USNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $239.24M
- P/E
- -11.47
- Fwd P/E
- 23.53
- PEG
- 0.05
- P/S
- 0.27
- P/B
- 0.46
- EV/EBITDA
- 1.85
- Div Yield
- 0.00%
- Gross Margin
- 77.26%
- Op Margin
- 1.07%
- Net Margin
- -2.34%
- ROE
- -3.98%
- ROIC
- 1.62%
Latest fiscal year · YoY change
- Revenue
- $925.26M+8.3%
- Gross Profit
- $724.40M+6.7%
- Op Income
- $50.86M
- Net Income
- $10.76M-74.4%
- EPS
- $0.58-73.6%
- OCF Growth
- -63.4%
- FCF Growth
- -83.3%
- 52W High
- $23.59
- 52W Low
- $12.53
- 50D MA
- $14.37
- 200D MA
- $17.54
- Beta
- 0.67
- RSI (14)
- 40
- Avg Volume
- 193.94K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
USANA said the quarter was mixed, with improving Core Nutrition and Hiya momentum offset by softer Rise results and a lower full-year outlook.· November 4, 2026
- Core Nutrition showed better operating profitability and some Southeast Asia Pacific improvement, but active customers still fell 8% year over year and Greater China was a drag.
- Hiya improved after a tough first half: active monthly subscribers rose 18% sequentially, net sales returned to year-over-year growth, and management raised Hiya net sales outlook to $130 million.
- Rise Wellness remained lumpy, with club orders below expectations again; management lowered its outlook and said improving gross margin remains a priority.
- The company ended Q3 with $179 million in cash and no debt, while year-to-date cash from operations and free cash flow both improved materially.
- Management’s strategy remains centered on customer acquisition, loyalty, and expanding into retail and Amazon, with several product and incentive changes planned to roll out over 2027.
USANA did not state quarterly revenue or EPS on the call, but management said it now expects net sales approaching $900 million and adjusted EBITDA of approximately $77 million for the full year, down from a prior outlook of $80.5 million. Core Nutritional net sales are now assumed at roughly $740 million, $10 million below the most recent outlook, while Hiya net sales outlook was raised to $130 million. Cash from operations totaled $45 million year to date versus $26 million last year, free cash flow was $36 million, inventory was down 13% from the end of the year, and the company ended with $179 million in cash and no debt. Management also said 2026 could come in modestly below outlook if certain Rise retail orders shift into 2026’s first quarter, with the impact then expected to show up in 2027.
Kevin Guest framed the quarter as mixed but encouraged by early progress on USANA’s shift from a single-channel direct-selling model toward a more diversified omnichannel business. He said Core Nutrition is seeing better profitability and Southeast Asia Pacific improvement, Hiya is benefiting from improved customer acquisition and diversification beyond a single ad platform, and the company’s debt-free balance sheet supports continued investment. At the same time, he stressed that active customer growth remains the top priority in Core, Hiya still needs work on retention and profitability, and Rise needs better margins and more consistent results.
Doug Hekking said the updated outlook reflects softer Rise sales and deliberate investment in Hiya, partly offset by stronger Core profitability. He highlighted year-to-date cash from operations of $45 million, free cash flow of $36 million, and $179 million in cash with no debt, calling the balance sheet a source of flexibility for strategy execution. He also noted inventory was down 13% from year-end and said the company expects Hiya to build on third-quarter momentum with sequential growth in both net sales and adjusted EBITDA in Q4.
Analysts focused on what was different in Southeast Asia, how changes to the brand partner incentive plan will affect customer acquisition and loyalty, the product pipeline and marketing spend for 2027, Hiya’s margin tradeoffs as it scales, Rise’s lumpy club channel, and the tax rate. Management said Southeast Asia’s improvement reflected leadership changes, a successful incentive program, and reengagement from top brand partners. On incentives, they said the planned refinements are modest, aimed at improving retention and loyalty, and should roll out through 2027; on new products, they pointed to women’s and kids initiatives with launches expected in 2027. For Hiya, they said near-term margins can be pressured by acquisition spend and the half-price first order, but retail carries higher margins and should help over time. For Rise, they said club orders remain unpredictable but retail expansion, including Protein Pop Balance in Target, should build a more stable base. On taxes, management said the venture businesses and amortization at Hiya remain a headwind, and better operating traction is the best path to improvement.
The positive case from the call is that USANA is seeing early signs that its strategy is working: Core Nutrition improved in Southeast Asia Pacific, Hiya returned to year-over-year net sales growth, and retail expansion is starting to broaden the opportunity beyond direct selling. Management also said the balance sheet is strong, with no debt and $179 million in cash, giving it room to keep investing.
The main risks are that active customers in Core Nutrition are still down 8% year over year, Greater China remains weak, and Rise Wellness continues to depend on lumpy club orders that can shift between quarters. Management also acknowledged that Hiya’s growth can pressure near-term margins, and that the full benefit of incentive changes and new product launches will likely not show up until 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 59.1%
- Shares Outstanding
- 18.49M
- Float Shares
- 10.93M
of shares held by institutions
140 13F filers
Buy/sell ratio 0.70. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.44M | ▼ 117.00K |
| Pzena Investment Management LLC | 1.11M | ▼ 91.60K |
| Nantahala Capital Management, LLC | 988.54K | ▲ 178.47K |
| Renaissance Technologies LLC | 965.12K | ▲ 6.60K |
| Vanguard Group Inc | 934.32K | ▼ 134.72K |
| Dimensional Fund Advisors LP | 819.84K | ▼ 17.58K |
| Vanguard Capital Management LLC | 487.37K | 0 |
| Aqr Capital Management LLC | 408.09K | ▲ 111.67K |
| Vanguard Portfolio Management LLC | 373.59K | ▲ 10.21K |
| Charles Schwab Investment Management Inc | 272.21K | ▼ 60.90K |
| State Street Corp | 244.27K | ▼ 16.97K |
| Morgan Stanley | 231.51K | ▲ 67.15K |
Held by 181 ETFs
Biggest fund positions in USNA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 22, 26 | WOOD TIMOTHY E | other | 1,632 |
| Oct 22, 26 | WOOD TIMOTHY E | other | 408 |
| Oct 22, 26 | WOOD TIMOTHY E | other | 1,632 |
| Oct 22, 26 | Winssinger Frederic J | other | 1,632 |
| Oct 22, 26 | Winssinger Frederic J | other | 1,632 |
| Oct 22, 26 | Nixon J Scott | other | 1,632 |
| Oct 22, 26 | Nixon J Scott | other | 1,632 |
| Oct 22, 26 | FULLER GILBERT A | other | 1,632 |
| Oct 22, 26 | FULLER GILBERT A | other | 1,632 |
| Oct 22, 26 | Pelosi Peggie | other | 1,632 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our USNA coverage
Recent articles, reports, and earnings notes.
No research on USNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate USNA report →USANA Health Sciences Q3 Earnings Call Highlights
marketbeat.com · Nov 7
USANA Health Sciences, Inc. (USNA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
USANA Health Sciences (USNA) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 3
USANA Health Sciences Reports Third Quarter 2026 Results
businesswire.com · Nov 3
USANA BiOmega Earns ConsumerLab Seal of Approval for Quality and Purity
prnewswire.com · Nov 3
As Thanksgiving Nears, USANA CEO Kevin Guest Urges All to Rethink What Success Really Means
prnewswire.com · Nov 2
USANA Schedules Third Quarter 2026 Earnings Release and Conference Call
businesswire.com · Oct 12
USANA Health Sciences and University of Utah Athletics Announce New Partnership
prnewswire.com · Oct 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.